id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0218-0007,FDA,FDA-2003-E-0218,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Pharmacia Corporation of Pfizer Inc,Rule,Certificate Extending Patent Term,2007-03-15T04:00:00Z,2007,3,,,2025-10-27T16:39:33Z,,0,0,090000648048cb6b
FDA-2003-E-0218-0006,FDA,FDA-2003-E-0218,Notice of Final Determination from U.S. Patent and Trademark Office to Pharmacia Corporation of Pfizer Inc.,Other,Letter(s),2007-02-06T05:00:00Z,2007,2,,,2025-10-27T16:36:54Z,,0,0,090000648048cb6a
FDA-2003-E-0218-0005,FDA,FDA-2003-E-0218,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-10T05:00:00Z,2007,1,,,2025-10-27T16:26:29Z,,0,0,090000648048cb69
FDA-2003-E-0218-0004,FDA,FDA-2003-E-0218,Determination of Regulatory Review Period for Purposes of Patent Extension; INSPRA,Notice,General Notice,2006-06-19T04:00:00Z,2006,6,2006-06-16T04:00:00Z,,2025-10-27T16:17:52Z,71 FR 34944,0,0,090000648048cb68
FDA-2003-E-0218-0003,FDA,FDA-2003-E-0218,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-05-24T04:00:00Z,2006,5,,,2025-10-27T16:07:33Z,,0,0,090000648048cb67
FDA-2003-E-0218-0002,FDA,FDA-2003-E-0218,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-23T04:00:00Z,2006,5,,,2025-10-27T16:02:59Z,,0,0,090000648048cb64
FDA-2003-E-0218-0001,FDA,FDA-2003-E-0218,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-06-09T04:00:00Z,2003,6,,,2025-10-27T15:32:58Z,,0,0,090000648048cb17